StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics cash

Cash and short-term investments held at the end of each period.

Galectin Therapeutics's cash was $13.27M at Jun 30, 2026. For fiscal 2025 it was $17.72M, up 17.2% from the year before. Over ten years it grew -3.7% a year on average. The highest annual figure on record is $47.48M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.72M+17.2%
FY2024Dec 31, 2024$15.12M-41.1%
FY2023Dec 31, 2023$25.66M+38.0%
FY2022Dec 31, 2022$18.59M-53.1%
FY2021Dec 31, 2021$39.65M+46.1%
FY2020Dec 31, 2020$27.14M-42.8%
FY2019Dec 31, 2019$47.48M+475.3%
FY2018Dec 31, 2018$8.25M+170.3%
FY2017Dec 31, 2017$3.05M-80.1%
FY2016Dec 31, 2016$15.36M-40.6%
FY2015Dec 31, 2015$25.85M-11.3%
FY2014Dec 31, 2014$29.13M+177.7%
FY2013Dec 31, 2013$10.49M+12.0%
FY2012Dec 31, 2012$9.36M+46.4%
FY2011Dec 31, 2011$6.40M+8.6%
FY2010Dec 31, 2010$5.89M+2247.0%
FY2009Dec 31, 2009$251.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.27M-3.6%
Q1 FY2026Mar 31, 2026$14.11M+89.9%
Q4 FY2025Dec 31, 2025$17.72M+17.2%
Q3 FY2025Sep 30, 2025$11.53M-57.4%
Q2 FY2025Jun 30, 2025$13.77M-46.2%
Q1 FY2025Mar 31, 2025$7.43M-68.5%
Q4 FY2024Dec 31, 2024$15.12M-41.1%
Q3 FY2024Sep 30, 2024$27.06M+32.9%
Q2 FY2024Jun 30, 2024$25.60M+42.5%
Q1 FY2024Mar 31, 2024$23.56M+30.9%
Q4 FY2023Dec 31, 2023$25.66M+38.0%
Q3 FY2023Sep 30, 2023$20.36M+28.6%
Q2 FY2023Jun 30, 2023$17.97M-25.7%
Q1 FY2023Mar 31, 2023$18.00M-43.1%
Q4 FY2022Dec 31, 2022$18.59M-53.1%
Q3 FY2022Sep 30, 2022$15.83M-56.7%
Q2 FY2022Jun 30, 2022$24.18M-23.5%
Q1 FY2022Mar 31, 2022$31.61M+52.2%
Q4 FY2021Dec 31, 2021$39.65M+46.1%
Q3 FY2021Sep 30, 2021$36.60M+12.4%
Q2 FY2021Jun 30, 2021$31.60M-22.5%
Q1 FY2021Mar 31, 2021$20.76M-52.1%
Q4 FY2020Dec 31, 2020$27.14M-42.8%
Q3 FY2020Sep 30, 2020$32.56M-35.3%
Q2 FY2020Jun 30, 2020$40.77M-21.7%
Q1 FY2020Mar 31, 2020$43.33M+521.5%
Q4 FY2019Dec 31, 2019$47.48M+475.3%
Q3 FY2019Sep 30, 2019$50.34M+396.6%
Q2 FY2019Jun 30, 2019$52.04M+395.8%
Q1 FY2019Mar 31, 2019$6.97M+74.8%
Q4 FY2018Dec 31, 2018$8.25M+170.3%
Q3 FY2018Sep 30, 2018$10.14M+45.7%
Q2 FY2018Jun 30, 2018$10.50M+15.0%
Q1 FY2018Mar 31, 2018$3.99M-70.8%
Q4 FY2017Dec 31, 2017$3.05M-80.1%
Q3 FY2017Sep 30, 2017$6.96M-56.7%
Q2 FY2017Jun 30, 2017$9.13M–
Q1 FY2017Mar 31, 2017$13.64M–
Q4 FY2016Dec 31, 2016$15.36M–
Q3 FY2016Sep 30, 2016$16.06M–

More Galectin Therapeutics figures

See a number that looks wrong?